

RESEARCH

Open Access

Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF- α antagonists

Valentina Germano^{1†}, Maria Sofia Cattaruzza^{2†}, John Osborn², Aurora Tarantino^{1,3}, Roberta Di Rosa¹, Simonetta Salemi¹ and Raffaele D'Amelio^{1*}

Abstract

Background: Infections which complicate rheumatic diseases such as Rheumatoid Arthritis (RA) and Spondyloarthropathy (SpA) (Psoriatic Arthritis [PA] and Ankylosing Spondylitis [AS]), may cause significant morbidity and mortality. However, among the studies on the incidence rate (IR) of infections in such patients, very few have involved controls and the results have been controversial, probably due to methodological difficulties. To estimate infection rates in RA and SpA patients under disease-modifying anti-rheumatic drugs (DMARDs), corticosteroids (CS) and tumor necrosis factor (TNF) α antagonists, alone or combined, a single-centre retrospective observational cohort study has been performed.

Patients and methods: Incidence rates/100 patient-years of any infections were evaluated in RA and SpA outpatients observed in the period November 1, 2003 through December 31, 2009 and stratified according to therapy. Infection incidence rate ratios (IRR) were calculated using Poisson regression models which adjusted for demographic/clinical characteristics of the patients.

Results: Three hundred and thirtyone infections [318 (96.1%) non-serious and 13 (3.9%) serious] have been registered among 176 of the 341 patients (52%). The IR/100 patient-years of all infections was 36.3 ranging from 12.4 (DMARDs + CS) to 62.7 (anti-TNF α + CS). The most frequent infection site was respiratory tract, and bacteria were responsible for three quarters of all infections. In the multivariate analysis, adding anti-TNF α to DMARDs doubled the IRR compared to DMARDs alone, anti-TNF α + CS significantly tripled it, whereas anti-TNF α + CS + DMARDs only increased the risk 2.5 times. The degree of disease activity was strongly and significantly associated with the infection risk (severe or moderate versus mild, IRR = 4). Female sex was significantly associated with increased infection risk, while duration of disease and anti-influenza vaccination were protective, the latter even for cutaneous/soft-tissue (mainly herpetic) infections.

Conclusion: The combination anti-TNF α with CS was found to be the most pro-infective treatment, whereas DMARDs alone were relatively safe. Physicians, therefore, should be aware that there may be an increased risk of infection when using anti-TNF α and CS therapy together. Anti-influenza vaccination appears to provide broad protection, adding evidence to support its use in these patients, and deserves further study.

Keywords: Rheumatoid Arthritis, Spondyloarthropathy, Infection risk, anti-TNF α , DMARDs, Corticosteroids

* Correspondence: raffaele.damelio@uniroma1.it

†Equal contributors

¹Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, S. Andrea University Hospital, Via di Grottarossa 1039, 00189 Rome, Italy

Full list of author information is available at the end of the article

Infections which complicate rheumatic diseases such as Spondyloarthritis (SpA) (Psoriatic Arthritis [PA] and Ankylosing Spondylitis [AS]) and Rheumatoid Arthritis (RA), may cause significant morbidity and mortality [1-3]. However, among the studies on the incidence rate (IR) of infections in such patients, very few have involved controls and the results have been controversial, probably due to methodological differences.

A Dutch group found no significant difference between RA patients and controls regarding the IR of infections [4]. In contrast, other authors have noted an increased infection risk [5-7]; in particular, Doran et al. [7] in 609 US RA patients found a doubled risk of developing an objectively confirmed infection compared with a sample of 609 age- and sex-matched controls without RA. Contradictory results are probably, at least in part, a consequence of the different events studied, including overall, non-serious, serious or opportunistic infections, different patient groups or different statistical parameters [8]. Moreover, the high statistical power obtained from large patient populations is frequently counterbalanced by possible bias linked to the scarce availability of detailed clinical information [9,10], which may eventually compromise the outcome. Finally, also the type of study, randomized controlled trial or observational study, may make a difference, particularly in relation to the patient selection criteria. Although, to the best of our knowledge, studies comparing the infection risk between RA and SpA patients are lacking, the risk in the second patient group seems to be low [11].

More recently, with the introduction of biologics in therapy, infection susceptibility has increased. Consequently, some studies, have drawn attention not only to the disease itself, but also to immune suppression induced by corticosteroids (CS), non biological disease-modifying anti-rheumatic drugs (DMARDs) and biologics.

Data on infection risk generally show that DMARDs (mainly methotrexate [MTX]), are relatively safe, whereas there is little debate on the capacity of CS to increase infection susceptibility [12]. Doran et al. analyzing RA patients, mainly treated with DMARDs and CS, did not find an increased infection risk associated with DMARDs, whereas in a multivariate analysis they identified CS as a predictor of infections [13]. Lacaille et al. [9] demonstrated an increased risk of mild and serious infections in RA patients taking CS, but no increase for DMARDs. Partially in contrast, Bernatsky et al., in RA patients found the highest risk of serious infections with CS and immunosuppressive DMARDs [14]. Although several studies have documented the effectiveness of anti-tumor necrosis factor (TNF) α , conflicting results on the possible increase in the number and/or severity of infections have also been reported. In placebo-controlled trials evaluating each one of three TNF α blockers for RA patients, the rate of any infections

did not exceed the rate in the placebo group [15-17], while data from a meta-analysis suggest an increased risk for serious infections [18]. Indeed, data from the British Biologics Register estimated a 2-fold increased risk of serious infections [19] and a recent review [20] reported a 4-fold increased risk of serious bacterial infections in RA patients. In the analysis of the RABBIT German Registry, the risk of serious infections was directly related to the dose of CS, especially when associated with TNF α .

The aim of this retrospective observational cohort study was to evaluate the impact of DMARDs, CS and the three TNF α antagonists licensed in Italy between 2001 and 2005, in mono or combination therapy, on non-serious and serious infections in RA and SpA patients.

Patients and methods

All the RA and SpA (PA and AS) outpatients observed at the Immuno-rheumatology Division of the S. Andrea University Hospital, Rome, during the period November 2003-December 2009 were evaluated and IRs/100 patient-years of non-serious and serious infections were calculated. RA, PA and AS were diagnosed on the basis of the recommendations of the 1987 American College of Rheumatology [21], Moll and Wright [22] and modified New York criteria [23], respectively. Patients were checked at 3-month intervals and stratified according to the type of therapy: DMARDs alone, DMARDs + CS, anti-TNF α alone, anti-TNF α + CS, anti-TNF α + DMARDs and anti-TNF α + DMARDs + CS. The anti-TNF α therapy was introduced following accepted guidelines [Disease Activity Score (DAS) on 44 joints > 3.7 or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) > 4] in the absence of contraindications. In particular, patients were excluded in the presence of any active infection after screening with the tuberculin skin test (TST), chest radiograph and hepatitis B (HBV) and C (HCV) viral markers. TST positive patients underwent microbiological and further radiological assessment, in order to exclude active overt disease. In patients without active disease, isoniazid was administered for at least 2 months before starting biological therapy and continued for a total of 6-9 months [24,25]. HBV active and inactive carriers underwent an anti-viral therapy or prophylaxis, respectively, whereas occult carriers were treated with biologics. In this case, viral markers including DNA levels and hepatic function were monitored throughout therapy [26,27]. HCV-antibody positivity was not considered a cause of exclusion, but, in the case of HCV viremia, specific anti-viral treatment before and quantitative viral evaluation and serum alanine aminotransferase monitoring after biological therapy was suggested [27,28].

The Ethics Committee of the S. Andrea University Hospital approved the study (approval number 132/2012). All infections occurring during treatment were noted either at planned or at patient solicited medical checks

for any new onset clinical event. Patients were actively, but only orally, solicited to immediately notify any possible adverse event occurring during the treatment, especially infections. These infections were actively looked for and diagnosed on the basis of clinical assessment and response to anti-infective treatment. Only the infections reported in the medical records collected during outpatient visits were considered. Moreover, they were classified according to demonstrated (by imaging and/or microbiological analyses) or presumed etiology (bacterial, viral and/or fungal) and site (respiratory, uro-genital, gastrointestinal, skin and soft tissue, bone and joints). Among respiratory infections, influenza-like-illness (ILI) episodes have been identified on the basis of the following clinical parameters: “acute respiratory tract infection and fever $\geq 38^{\circ}\text{C}$ accompanied by systemic or respiratory symptoms” [29]. Moreover infections were defined as either serious when life-threatening, requiring hospitalization and/or intravenous anti-infective treatment, or non-serious when only requiring a physician visit and/or use of not intravenous anti-infective medications. Comorbidities (diabetes mellitus, leukopenia, chronic obstructive pulmonary disease [COPD]) and smoking status, were considered. Disease activity was classified as mild, moderate and severe when DAS was <2.4 , $2.4\text{--}3.7$, >3.7 and BASDAI 1–3, 4–7 and 8–10, respectively. Anti-influenza and anti-pneumococcal vaccinations, only administered to patients with mild/moderate disease activity in order to prevent any flare up, were recorded.

Statistical analysis

Proportions were calculated for the demographic and clinical characteristics of all patients. For important clinical characteristics, IRs, defined as the number of observed events (infections)/100 patient-years of follow-up, were calculated, to estimate the risk of infection in the different groups. Also, Incidence Rate Ratios (IRR) and their statistical significance were obtained from Poisson regression analysis. In crude analyses, statistical differences were evaluated by χ^2 tests and Fisher’s exact test. Variables considered as potential confounders or independent predictors of developing an infection, were included in the Poisson regression model according to univariate results and clinical considerations. Adjusted robust IRR and confidence intervals were calculated using an extra-Poisson variation regression model. Compared to the usual Poisson regression model, this gives the same estimates but wider confidence intervals (through greater standard errors). All analyses were performed using Stata (Stata College Station, TX version 8).

Results

Demographic and clinical characteristics of patients and infection rates are reported in Table 1. The patients

provided a total of 911.8 patient-years of follow-up, with a median follow-up time of 26.04 months (interquartile range 13.77 to 47.28), in particular 21.4% of patients were followed for 12 months or less and 23.2% for more than 48 months. One-hundred and seventy-six (52%) patients had at least 1 infection, the total infections being 331 (96.1% non-serious versus 3.9% serious; mean infections/patient 1.9, range 1–8).

The infection rate in the first 6 months of treatment was 3.8 per 100 patient-months, and in the subsequent semesters was 3.3, 3.3, 2.7 and 3.0. The chi squared test for the comparison of the semesters and the test for trend are not statistically significant.

The difference between the rates for males and females was statistically significant, females being at increased risk. There was a tendency for the rate to decrease with increasing age-group, but this was not statistically significant. The rates for the two types of diseases, RA and SpA, were similar. The rate increased with disease activity, especially for the “moderate” and “severe” categories; however the very low rate observed for the “mild” group was based on few cases. The risk showed a decreasing trend with disease duration, but this was not statistically significant. Vaccination against influenza and the absence of comorbidities tended to reduce the infection rates, but these were not statistically significant at the 5% level.

The sites and types of non-serious and serious infections are reported in Table 2. One male patient under anti-TNF α + CS therapy died from pneumonia of presumed viral etiology, whereas no other mortality or permanent sequelae were observed as a consequence of infections. Moreover, 16/229 (7%) anti-TNF α -treated patients were positive at TST screening, without radiological and/or microbiological tubercular findings. All of them underwent prophylactic treatment two months before starting biologics and no tuberculosis reactivation was observed in the follow-up. Finally, no HBV surface antigen positivity was found, whereas HBV core antibodies were positive in 12% of patients; all were investigated for HBV viremia with negative results, and thus they were considered potential occult HBV carriers [25]. No HBV reactivation was observed in these patients during the follow-up. Three observed HCV positive cases, one of whom also positive for viremia, were treated with biologics (the patient with viremia only after a pegylated interferon and ribavirin three-month treatment course), without viral reactivation.

The IR/100 patient-years for all infections was 36.3 (95% CI from 32.4 to 40.3), but it was higher in the presence of anti-TNF α therapy than with DMARDs alone (the control or reference group) or with CS, as reported in Table 1. When anti-TNF α therapy was combined, especially with CS, the infection risk significantly increased. DMARDs

Table 1 Demographic and clinical characteristics of patients and crude infection rates/100 patient-years according to the type of treatment

	DMARDs	DMARDs + CS	Anti-TNFa	Anti-TNFa + CS	Anti-TNFa + DMARDs	Anti-TNFa + DMARDs + CS	All patients
Patients N	30	82	24	42	42	121	341
Gender							
Male	8	15	12	13	11	34	93
Female	22	67	12	29	31	87	248
Age							
<50	9	15	12	17	14	38	105
50-59	9	22	3	7	8	29	78
60-69	5	22	6	4	13	34	84
≥70	7	23	3	14	7	20	74
Type of disease							
RA	9	64	8	29	23	90	223
SpA	21	18	16	13	19	31	118
Disease duration							
<5 years	21	41	7	6	14	28	117
5-9 years	2	29	3	18	11	43	106
≥10	7	12	14	18	17	50	118
Vaccination for influenza							
Yes	5	24	4	18	17	57	125
No	25	58	20	24	25	64	216
Comorbidities and smoking							
Yes	13	24	17	16	21	55	146
No	17	58	7	26	21	66	195
All infections N	7	29	16	70	43	166	331
Serious infections N	0	0	1	2	2	8	13
Patient-years	49.2	233.5	52.7	111.6	103.9	360.9	911.8
Infections /100	14.2	12.4	30.4	62.7	41.4	46.0	36.3
Patient-years							
p value	Reference group	0.721	0.09	0.00001	0.0039	0.0003	-

CS: Corticosteroids; DMARDs: Disease Modifying Anti-Rheumatic Drugs; TNF: Tumour Necrosis Factor.

(90% MTX) and CS (prednisone) were administered at low-dose (10–15 mg/weekly and <10 mg/daily, respectively). The IR/100 patient-years for serious infections was 1.4.

The adjusted results obtained from the Poisson regression are reported in Table 3. These results are broadly similar to the crude comparisons. However, the adjusted analysis implied a significant increase for females, a significant decrease in the risk with increased duration of the disease and influenza vaccination was significantly protective towards infections, in particular towards skin and soft tissue infections as shown in Table 4.

Discussion

In this study, an IR/100 patient-years of 36.3 was observed for all infections in 341 RA and SpA patients,

being 34.9 for non-serious and 1.4 for serious infections. These results are similar to those reported from the CORRONA Register on a larger RA US patient population (32/100 patient-years) [30], while other studies have reported higher (48.2) [31] and lower rates (22.6, 28.3 and 6.8 for treatment with Etanercept, Infliximab and non biological DMARDs, respectively) [32]. For serious infections, the rate observed in this study is generally lower than those observed in other studies, excepting that in the CORRONA Register, where the IR was 0.8/100 patient-years for hospitalized infections [30]. The IRs/100 patient-years for serious infections are, in fact, higher in the German Biologics Register (6.4, 6.2 and 2.3, for treatment with Etanercept, Infliximab and non biological DMARDs, respectively) [32] and in the British Register (5.3 and 4.1

Table 2 Site and type of non-serious and serious infections

	Non-serious N (%)	Serious N (%)	Total N (%)
Site of infection	318 (96.1)	13 (3.9)	331 (100)
Respiratory	120 (36.3)	7 (2.1)	127 (38.4)
Uro-genital	111 (33.5)	0	111 (33.5)
Skin and soft tissue	66 (20.0)	4 (1.2)	70 (21.2)
Gastrointestinal	21 (6.3)	0	21 (6.3)
Bone	0	2 (0.6)	2 (0.6)
Type of infection*			
Bacterial*	236 (71.3)	12 (3.6)	248 (74.9)
<i>Escherichia coli</i>	40 (12.1)	0	40 (12.1)
<i>Staphylococcus aureus</i>	4 (1.2)	4 (1.2)	8 (2.4)
<i>Proteus mirabilis</i>	3 (0.9)	0	3 (0.9)
<i>Klebsiella pneumoniae</i>	2	0	2
<i>Serratia marcescens</i>	1	0	1
<i>Yersinia spp</i>	1	0	1
<i>Chlamydia trachomatis</i>	1	0	1
Viral*	61(18.4)	1	62 (18.7)
Herpes simplex	40 (12.1)	0	40 (12.1)
VZ virus	8 (2.4)	0	8 (2.4)
Fungal*	21 (7)	0	21 (7)
<i>Candida albicans</i>	5 (24)	0	5 (24)
<i>Malassezia furfur</i>	4 (19)	0	4 (19)

*It was not possible to identify micro-organism for all infections.

for biologics and non biological DMARDs, respectively) [19]. In a recently published multicenter retrospective cohort study, RA patients had IRs 8.2 versus 7.8 for biologics versus non biological DMARDs, and for psoriasis/spondyloarthritis the rates were 5.4 versus 5.4 respectively [10]. Moreover, an Italian RA population study [33] reported an IR 3.6.

The percentage of patients infected among those treated with DMARDs and biologics is seldom reported, but varies from 13% [32], through 23% [30] and 34.5% [31], to 51% [34]. Among the cases described here, it is 176/341, 52% (146 [83%] of whom were treated with biologics and 111 [63%] of them also with CS in addition to biologics). Despite the difficulty of providing an interpretation of this variability, as proposed by Salliot et al. [31], the different percentages of patients on CS and/or anti-TNF α therapies may in part account for the observed variation. Indeed, in the current study, the proportions of patients treated with anti-TNF α (229/341 [67%]) or with CS (245/341 [72%]) (anti-TNF α and CS associated in 163/341 [48%]) are higher than in other studies (45% and 24% respectively in Au et al. [30]), but lower, for CS, than in the German Biologics Register [32], where it was 82%.

Infections were mainly (> 90%) respiratory, uro-genital or cutaneous/soft tissue, as found by others [31,32]. Skin and soft tissue infections were considered important in patients under anti-TNF α therapy even in 2006 [20,35], probably as a consequence of the TNF α role in cutaneous immunity [36]. TNF α , in fact, is a key cytokine responsible for cutaneous endothelial activation and thereby

Table 3 Poisson regression incidence rate ratios

	Crude IRR	Adjusted IRR	95% CI		p
Gender female vs male	1.26	1.37	1.01	1.86	0.042
Age (effect per 10 years)	0.88	0.95	0.86	1.05	0.302
Disease duration 5–9 vs <5 years	0.92	0.67	0.48	0.93	0.016
Disease duration 10+ vs <5 years	0.82	0.61	0.45	0.83	0.002
DMARDs + CS vs DMARDs [^]	0.87	0.76	0.34	1.68	0.493
Anti-TNF α vs DMARDs [^]	2.14	1.57	0.55	4.51	0.400
Anti-TNF α + CS vs DMARDs [^]	4.42	3.60	1.58	8.20	0.002
Anti-TNF α + DMARDs vs DMARDs [^]	2.92	2.11	0.95	4.71	0.067
Anti-TNF α + DMARDs + CS vs DMARDs [^]	3.24	2.54	1.15	5.59	0.021
Presence of comorbidities* and smoking	1.22	1.07	0.85	1.37	0.554
Anti-influenza Vaccine	0.84	0.73	0.57	0.94	0.016
Moderate Disease Activity vs Mild at baseline	5.95	4.12	1.24	13.68	0.021
Severe Disease Activity vs Mild at baseline	11.29	4.28	1.21	15.08	0.024
SpA vs RA	0.91	0.96	0.67	1.38	0.817

*presence of at least one of the following comorbidities: COPD, diabetes and leukopenia.

[^]DMARDs = control group.

COPD: Chronic Obstructive Pulmonary Disease; CS: Corticosteroids; DMARDs: Disease Modifying Anti-Rheumatic Drugs; RA: Rheumatoid Arthritis; SpA: Spondyloarthropathies; TNF: Tumour Necrosis Factor. IRR:Incidence Rate Ratio, CI: confidence interval.

Table 4 Effect of influenza vaccination on respiratory, uro-genital, skin/bone/soft tissue and gastro-enteric infection risk

Site of infections	Influenza vaccination	Number of infections	Patient-years of follow-up	Rate	p
Respiratory	No	74	165.57	0.447	0.666
	Yes	53	128.26	0.413	
Uro-genital	No	58	117.92	0.492	0.781
	Yes	53	113.65	0.466	
Skin/Bone/Soft tissue	No	52	61.91	0.840	0.0001
	Yes	20	85.49	0.234	
Gastro-enteric	No	13	28.09	0.463	0.229
	Yes	8	29.84	0.268	

recruitment of inflammatory cells to the skin. Moreover, it is also important in the mobilization of cutaneous antigen-presenting cells (Langerhans cells) from the epidermis to draining lymph nodes [37,38]. The virulence of *Staphylococcus aureus* is confirmed, having been isolated in over 30% of the serious infections. Contrary to Favalli et al. [33], in this study there were no cases of active tuberculosis, probably because the patients were enrolled after 2001 [39], when sensitivity to possible tubercular reactivation in anti-TNF α -treated patients became very high. The percentage of HBV core antibody positivity is lightly higher than, but not significantly different from, that reported by Caporali et al. (12% versus 9%) [40]. Lack of HCV reactivation in the three treated patients is in line with the literature [28,41].

IRs/100 patient-years in the different patient groups stratified according to treatment type range from 12.4 (DMARDs + CS), to 14.2 (DMARDs), to 30.4 (anti-TNF α alone), to 41.4 (anti-TNF α + DMARDs), to 46.0 (anti-TNF α + DMARDs + CS) to 62.7 (anti-TNF α + CS). Thus, CS behave as immunosuppressants when associated with anti-TNF α , but are less influential when combined with DMARDs, whereas biologics seem to be associated with enhanced infection risk. In contrast to other authors [10,42,43], we did not observe a temporary increase of infection risk in the first period after start of immunosuppressive therapy.

The multivariate analysis shows that the type of disease (RA or SpA) does not significantly affect the infection risk (IRR 0.96), therefore the two patient groups have been considered as a single population. This may be probably due to a sort of “balancing” effect of immunosuppressive therapy on the different infection risk of RA and SpA *per se*. Comorbidities have not been found to significantly affect the infection risk (IRR 1.07), but the confidence interval is wide (0.85-1.37). It would be interesting to investigate the effects of the single comorbidities and combinations of them, but the sample size is too small for an analysis of this type. However, in females, the infection risk is increased by more than one third, as already observed by Lacaille et al. [9] and by Au

et al. [30]. Female gender as a pro-infective element may be linked to the impact of uro-genital infections which are more common in females [44]. Disease duration is generally considered a risk factor for infections [19,45], whereas in this study, surprisingly, it was protective. The crude effects are not statistically significant, but disease duration is very likely to be confounded with other factors, for example age, the presence of comorbidities and disease activity, and this may explain the increased and statistically significant effect observed in the adjusted analysis. Indeed, protection may be linked to the high proportion (> 90%, data not shown) of patients with mild-moderate disease activity during the follow-up (patients with ≥ 2 years of treatment) as a consequence of treatment effectiveness. Despite the limited evidence regarding the impact of the disease activity on the susceptibility for infections [46], recently Au et al. found that higher disease activity was associated with a higher probability of developing hospitalized infections [30]. In the current study, baseline disease activity is closely associated with infection risk, with an IRR of 4.3 and 4.1 for severe and moderate versus mild disease activity, respectively. Chronic inflammatory diseases and infections are both interwoven with disease activity. High disease activity, in fact, is the expression of chronic inflammatory state, which in turn may suppress the immune system [47], thus making the development of infectious diseases easier. Conversely, infections may strongly stimulate the immune system, thus enabling, through inflammation, the underlying disease to reactivate. Both processes are able to increase the level of the indices for disease activity.

The most interesting results come from treatment type. Anti-TNF α alone increases the IRR and when combined with CS more than triples it compared with DMARDs alone. Moreover, DMARDs seem to provide protection against infection in patients taking biologics, CS and DMARDs together, compared with biologics and CS alone, the IRR being 2.5, instead of 3.6. In agreement with recent studies, which have identified a significant risk for non-serious [7-9,48] and serious [8-14,46,49-52] infections for even low-dose CS (< 10 mg/day of prednisone)

the current study confirms that they are pro-infective and thus likely immunosuppressive, especially if combined with anti-TNF α . Moreover, the association CS/anti-TNF α therapy has been recently described as strong predictor of serious infections in RA [46,52,53]. Biologics were instead associated with a net increased infection risk, mainly when administered with CS. DMARDs (mainly MTX) appear to be safer regarding infection risk, with an IR/100 patient-years (12.9) comparable to that (12.87) observed by Doran et al. [7] in non RA controls. The apparent lack of MTX pro-infective action, or rather its possible protective effect, has already been reported [9,19]. This may be partly related to its anti-methylenetetrahydrofolate reductase activity, which is able to inhibit bacterial [54] and viral [55,56] proliferation. The important increase in the risk of infection associated with the combined treatment CS + anti-TNF α may instead be because CS, in addition to the induction of apoptosis on T lymphocytes [57], are able to reduce cytokine production [57]. This includes TNF α which appears to be the most sensitive [58]. Anti-TNF α therapy is only able to inactivate TNF α , which is increased in RA patients, without effect on its synthesis. This may, instead, be inhibited by CS [59]. Anti-TNF α agents, on the other hand, may reverse the TNF α -induced CS resistance in RA, by restoring the TNF α -inhibited glucocorticoid receptor function [60,61]. The CS/anti-TNF α combination, therefore, synergizes in lowering TNF α levels through different and independent mechanisms, with consequent enhanced anti-inflammatory effect, but at the expense of a raised infection risk [52]. Physicians, therefore, should be aware that there may be an increased risk of infection, when using CS and anti-TNF α therapy together. However, this result is not obtained from a randomized clinical trial. There may be residual confounding due to factors which have not been included in this study, which could explain the association between increased risk of infection and the combination of CS and anti-TNF α therapy. Thus, the topic deserves further studies.

As found by Schneeweiss et al., patients treated with anti-TNF α were more likely to have received at least one influenza vaccination [50]. Moreover, having been vaccinated at least once against influenza was found to be significantly protective towards the overall risk of infection in the multivariate analysis. This observation appears important, but there are caveats. First, lack of solid evidence of influenza vaccine efficacy in immunosuppressed populations [62,63]; second, the impossibility to establish a correlation between vaccine administration and protection from virologically confirmed influenza in the same year; third, the finding that vaccination is protective against all infections, with varying IRR, but significantly ($p < 0.001$) only for skin/bone/soft tissue infections. However, although vaccination may be confounded with

unrelated factors, such as compliance with long term medication, or the preferential recruitment of patients with mild/moderate disease activity among the vaccinees, its effect should be reduced or eliminated in a regression model which takes account of these factors. On the contrary, our results imply that the protective effect of vaccination is increased and remains statistically significant after adjustment for these variables. The very low number of ILI episodes (14 patients, 2 of whom vaccinated and 12 non vaccinated) may explain the lack of statistical significance for ILI. Moreover, the high statistical significance found for skin/bone/soft tissue infections, (the majority of which were herpetic [$> 55\%$]), may perhaps be associated with a specific protective action. This observation is in agreement with Miller JB who in 1979 reported that flu vaccine reduced discomfort produced by both, influenza and herpes infections [64]. Furthermore, it has recently been demonstrated that a significantly higher anti-influenza response is induced by a plasmid influenza nucleoprotein DNA vaccine combined with herpes simplex virus (HSV) viral protein 22 gene. This may imply a high level of cross-induced anti-influenza protection by HSV antigen [65].

This study has potential limitations because it is a retrospective analysis of observed clinical results. There was no *a priori* consideration of sample size and power because the patients included were those observed in the Immuno-rheumatology Division during the selected time period. However, it can be calculated that, although the number of patients is relatively low, the study would have had a power of more than 99% to detect the observed difference between treatment with DMARDs + CS and treatment with anti-TNF α + CS significantly at the 5% level. The relatively small sample size may lead to some real associations not being detected and confidence intervals may be so wide as to include clinically important values. Moreover, the low sample size may be offset by the study being single-centre, thus eliminating inter-centre variability, which may prevent under-ascertainment and/or misclassification of infectious events or other clinical information.

Another potential source of bias is inherent in the design of the study. The patients included in the study were those who attended the Immuno-rheumatology Clinic during a fixed period of time; that is, they were prevalent cases (in the period) not incident. This may have led to a higher probability of inclusion for patients with long duration of disease, that is patients with a better prognosis. Given that the time interval for inclusion was relatively long, six years, we believe this bias is unlikely to have had a great effect on the conclusions regarding the incidence of infections in the treatment groups.

A further limitation of the study is the lack of matching among groups exposed to different therapeutic protocols

(Table 1), but this is a direct and unavoidable consequence of the study type. Moreover, the evaluation of infection risk for RA and SpA patients together, has been performed following the non-significant comparison between RA and SpA in the multivariate regression. It could be hypothesized that immunosuppressive therapy may have balanced the infection risk between the two different pathological conditions. Finally, comorbidities have been analyzed as a whole and not singularly because of the small number of cases in each; this may miss some important effects and may account for discrepancies observed with some literature data.

Conclusion

In conclusion, this study suggests a high pro-infective potential of the combination of anti-TNF α agents and CS, and provides a biological interpretation of the synergy. According to EULAR [66] recommendations, CS should be tapered as soon as possible. Indeed, our results suggest that, even though CS may delay radiographic joint damage [67], they should be used carefully with biologics. The search for personalized treatment options should be driven by these considerations, trying to maintain with DMARDs the remission phases induced by biologics, as indicated by EULAR [66]. The observed association between influenza vaccination and skin, bone, soft tissue infections has never been described before, to the best of our knowledge, is interesting, and deserves further study. Thus this may represent a further rationale for the already recommended administration of influenza vaccine to these patients [68-70]. However, larger prospective studies analyzing the role of CS, non biological DMARDs and single biologics on infection risk should be planned and implemented, in order to give a definitive answer to the question of the safety for the immune system of these treatments and their cost effectiveness.

Abbreviations

AS: Ankylosing spondylitis; BASDAI: Bath ankylosing spondylitis disease activity index; COPD: Chronic obstructive pulmonary disease; CS: Corticosteroids; DAS: Disease activity score; DMARDs: Disease-modifying anti-rheumatic drugs; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HSV: Herpes simplex virus; ILI: Influenza-like-illness; IR: Incidence rate; IRR: Incidence rate ratios; MTX: Methotrexate; PA: Psoriatic arthritis; RA: Rheumatoid arthritis; SpA: Spondyloarthropathies; TNF α : Tumor necrosis factor; TST: Tuberculin skin test.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors have made substantial contribution to conception and design, acquisition, analysis or interpretation of data. They were involved in drafting the article or writing it critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements

We thank Maria Laura Sorgi, Bruno Laganà and Andrea Picchianti Diamanti for helping in data collection.

Author details

¹Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, S. Andrea University Hospital, Via di Grottarossa 1039, 00189 Rome, Italy. ²Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy. ³Current address: Italian Air Force, Logistic Command, Health Service, Viale dell'Università 4, 00185 Rome, Italy.

Received: 19 November 2013 Accepted: 13 March 2014

Published: 22 March 2014

References

1. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H: Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. *Clin Exp Rheumatol* 1995, **13**:149-153.
2. Gonzalez A, Kremers MH, Crowson CS, Nicola PJ, Davis JM, Therau TM, Roger VL, Gabriel SE: The widening mortality gap, between rheumatoid arthritis patients and the general population. *Arthritis Rheum* 2007, **56**:3583-3587.
3. Vanderbroucke JP, Hazevoet HM, Cats A: Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. *J Rheumatol* 1984, **11**:158-161.
4. Van Albeda-Kuipers GA, Linthorst J, Peeters EA, Breedveld FC, Dijkmans BA, Hermans J, Vandenbroucke JP, Cats A: Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. *Arthritis Rheum* 1988, **31**:667-671.
5. Baum J: Infection in rheumatoid arthritis. *Arthritis Rheum* 1971, **14**:135-137.
6. Vandenbroucke JP, Kaaks R, Valkenburg HA, Boersma JW, Cats A, Festen JJ, Hartman AP, Huber-Bruning O, Rasker JJ, Weber J: Frequency of infections among rheumatoid arthritis patients, before and after disease onset. *Arthritis Rheum* 1987, **30**:810-813.
7. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. *Arthritis Rheum* 2002, **46**:2287-2293.
8. Askling J, Dixon WG: The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. *Curr Opin Rheumatol* 2008, **20**:138-144.
9. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM: Use of non biologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. *Arthritis Rheum (Arthritis Care Res)* 2008, **59**:1074-1081.
10. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR: Initiation of Tumor Necrosis Factor- α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. *JAMA* 2011, **306**:2331-2339.
11. Fouqué-Aubert A, Jette-Paulin L, Combesure C, Basch A, Tebib J, Gossec L: Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. *Ann Rheum Dis* 2010, **69**:1756-1761.
12. Winthrop KL: Infectious and biologic therapy in Rheumatoid Arthritis. Our changing understanding of risk and prevention. *Rheum Dis Clin N Am* 2012, **38**:727-745.
13. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Predictors of infection in Rheumatoid Arthritis. *Arthritis Rheum* 2002, **49**:2294-2300.
14. Bernatsky S, Hudson M, Suissa S: Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. *Rheumatology (Oxford)* 2007, **46**:1157-1160.
15. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Infliximab and methotrexate in the treatment of rheumatoid arthritis. *N Engl J Med* 2000, **343**:1594-1602.
16. Kareskog L, van der Heijde D, De Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M: TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004, **363**:675-681.
17. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG: Long-term efficacy and safety of adalimumab plus methotrexate in patients

- with rheumatoid arthritis: ARMADA 4-year extended study. *Ann Rheum Dis* 2005, **65**:753–759.
18. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: **Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.** *JAMA* 2006, **295**:2275–2285.
 19. Dixon WG, Watson K, Lunt M: **Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Results From the British Society for Rheumatology Biologics Register.** *Arthritis Rheum* 2006, **54**:2368–2376.
 20. Furst DE: **The risk of infections with biologic therapies for rheumatoid arthritis.** *Semin Arthritis Rheum* 2010, **39**:327–346.
 21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: **The American Rheumatism Association 1987 Revised criteria for the classification of rheumatoid arthritis.** *Arthritis Rheum* 1988, **31**:315–324.
 22. Moll JM, Wright V: **Psoriatic arthritis.** *Semin Arthritis Rheum* 1973, **3**:55–78.
 23. Goie The HS, Steven MM, van der Linden SM, Cats A: **Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis.** *Br J Rheumatol* 1985, **24**:242–249.
 24. British Thoracic Society Standards of care Committee: **BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF- α treatment.** *Thorax* 2005, **60**:800–805.
 25. Gómez-Reino JJ, Carmona L, Descalzo AM, Biobadaser Group: **Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.** *Arthritis Rheum* 2007, **57**:756–761.
 26. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagioli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A, For the Italian Association for the Study of Liver (AISF): **Prophylaxis and treatment of hepatitis B in immunocompromised patients.** *Dig Liver Dis* 2007, **39**:397–408.
 27. Viganò M, Degasperis E, Aghemo A, Lampertico P, Colombo M: **Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management.** *Expert Opin Biol Ther* 2012, **12**:193–207.
 28. Ferri C, Ferracioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, Valesini: **GISEA Group: Safety of anti-tumor necrosis factor- α therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.** *J Rheumatol* 2008, **35**:1944–1949.
 29. Pregliasco F, Puzelli S, Mensi C, Anselmi G, Marinello R, Tanzi ML, Affinito C, Zambon MC, Donatelli I, The Collaborative Group Influchild: **Influenza virological surveillance in children: the use of the Quickvue rapid diagnostic test.** *J Med Virol* 2004, **73**:269–273.
 30. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE, CORRONA investigators: **High disease activity is associated with an increased risk of infection in patient with rheumatoid arthritis.** *Ann Rheum Dis* 2011, **70**:785–791.
 31. Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, Dougados M: **Infections during tumor necrosis factor- α -blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.** *Rheumatology (Oxford)* 2007, **46**:327–334.
 32. Listing J, Strangfeld A, Kary S, Rau R, Von Hinuber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A: **Infections in patients with rheumatoid arthritis treated with biologic agents.** *Arthritis Rheum* 2005, **52**:3403–3412.
 33. Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, Gorla R, Filippini M, Marchesoni A: **Serious infections during anti-TNF α treatment in rheumatoid arthritis patients.** *Autoimmun Rev* 2009, **8**:266–273.
 34. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: **A trial of Etanercept, a recombinant Tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.** *N Engl J Med* 1999, **340**:253–259.
 35. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, Watson KD, Lunt M, Hyrich KL, Symmons DP: **Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.** *Ann Rheum Dis* 2013, **72**:229–234.
 36. Groves RW, Allen MH, Ross EL, Barker JN, MacDonald DM: **Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression.** *Br J Dermatol* 1995, **132**:345–352.
 37. Vestergaard C, Johansen C, Otkjaer K, Deleuran M, Iversen L: **Tumor necrosis factor induced CTACK/CCL27 (cutaneous T cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor kappa B.** *Cytokine* 2005, **29**:49–55.
 38. Griffiths CE, Dearman RJ, Cumberbatch M, Kimber I: **Cytokines and Langerhans cell mobilisation in mouse and man.** *Cytokine* 2005, **32**:67–70.
 39. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: **Tuberculosis associated with infliximab, a tumor necrosis factor-neutralizing agent.** *N Engl J Med* 2001, **345**:1098–1104.
 40. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P: **Safety of Tumor Necrosis Factor Blockers in Hepatitis B Virus Occult Carriers (Hepatitis B Surface Antigen Negative/Anti-Hepatitis B Core Antigen Positive) With Rheumatic Diseases.** *Arthritis Care Res* 2010, **62**:749–754.
 41. Brunasso AMG, Puntoni M, Gulia A, Massone C: **Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.** *Rheumatology* 2011, **50**:1700–1711.
 42. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP, BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register: **Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.** *Rheumatology (Oxford)* 2011, **50**:124–131.
 43. Asklung J, Foreid CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Van Vollenhoven RF, Klareskog L: **Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.** *Ann Rheum Dis* 2007, **66**:1339–1344.
 44. Hooton TM: **Clinical practice. Uncomplicated urinary tract infection.** *N Engl J Med* 2012, **366**:1028–1037.
 45. Coyne P, Hamilton J, Haycock C, Saravanan V, Coulson E, Kelly CA: **Acute lower respiratory tract infections in patients with rheumatoid arthritis.** *J Rheumatol* 2007, **34**:1832–1836.
 46. Listing J, Gerhold K, Zink A: **The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.** *Rheumatology* 2013, **53**:53–61.
 47. Kanterman J, Sade-Feldman M, Baniyash M: **New insights into chronic inflammation-induced immunosuppression.** *Semin Cancer Biol* 2012, **22**:307–318.
 48. Dixon WG, Kezouh A, Bernatsky S, Suissa S: **The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study.** *Ann Rheum Dis* 2011, **70**:956–960.
 49. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM: **The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.** *Am Acad Dermatol* 2011, **64**:1035–1050.
 50. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH: **Anti-tumour necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.** *Arthritis Rheum* 2007, **56**:1754–1764.
 51. Wolfe F, Caplan L, Michaud K: **Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.** *Arthritis Rheum* 2006, **54**:628–634.
 52. Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G: **Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.** *Autoimmun Rev* 2012, **12**:225–229.

53. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J: **Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?** *Ann Rheum Dis* 2011, **70**:1914–1920.
54. Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML: **The structure and properties of methylenetetrahydrofolate reductase from *Escherichia coli* suggest how folate ameliorates human hyperhomocysteinemia.** *Nat Struct Biol* 1999, **6**:359–365.
55. Bronowicki JP, Abdelmoutaleb I, Peyrin-Biroulet L, Venard V, Khiri H, Chabi N, Amouzou EK, Barraud H, Halfon P, Sanni A, Bigard MA, Le Faou A, Guéant JL: **Methylenetetrahydrofolate reductase 677 T allele protects against persistent HBV infection in West Africa.** *J Hepatol* 2008, **48**:532–539.
56. Fodil-Cornu N, Kozij N, Wu Q, Rozen R, Vidal SM: **Methylenetetrahydrofolate reductase (MTHFR) deficiency enhances resistance against cytomegalovirus infection.** *Genes Immun* 2009, **10**:662–666.
57. Lanza L, Scudeletti M, Puppo F, Bosco O, Peirano L, Filaci G, Fecarotta E, Vidali G, Indiveri F: **Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes.** *Clin Exp Immunol* 1996, **103**:482–490.
58. DeRijk R, Michelson D, Karp B, Petrides J, Galliven E, Deuster P, Paciotti G, Gold PW, Sternberg EM: **Exercise and Circadian Rhythm-Induced Variations in Plasma Cortisol Differentially Regulate Interleukin-1b (IL-1b), IL-6, and Tumor Necrosis Factor- α (TNF α) Production in Humans: High Sensitivity of TNF α and Resistance of IL-6.** *J Clin Endocrinol Metab* 1997, **82**:2182–2191.
59. Salemi S, Germano V, Picchianti Diamanti A, D'Amelio R: **Role of antibody-secreting cells as early biomarkers of immune response to influenza vaccination in Rheumatoid arthritis patients treated with anti-TNF α agents.** *Int J Clin Rheumatol* 2012, **7**:155–158.
60. Miller AH, Pearce BD, Ruzek MC, Biron CA: **Interactions between the hypothalamic-pituitary-adrenal axis and immune system during viral infection: pathways for environmental effects on disease expression.** In *Handbook of Physiology. Section 7: The Endocrine System.* New York, Oxford University Press, 2001, vol 4: *Coping with the Environment: Neural and Endocrine Mechanisms.* Edited by McEwen BS; 2001:425–450.
61. Gelfand EW: **Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases.** *N Engl J Med* 2012, **367**:2015–2025.
62. Kunisaki KM, Janoff EN: **Influenza in Immunosuppressed Populations: A Review of Infection Frequency, Morbidity, Mortality, and Vaccine Responses.** *Lancet Infect Dis* 2009, **9**:493–504.
63. Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanzuzdana A, Agboado G, Orton E, Béchard-Evans L, Morgan G, Stevenson C, Weston R, Mukaigawara M, Enstone J, Augustine G, Butt M, Kim S, Puleston R, Dabke G, Howard R, O'Boyle J, O'Brien M, Ahyow L, Denness H, Farmer S, Figuereroa J, Fisher P, Greaves F, Haroon M, Haroon S, Hird C, *et al*: **Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective.** *PLoS One* 2011, **6**:e29249.
64. Miller JB: **Treatment of active herpes virus infections with influenza virus vaccine.** *Ann Allergy* 1979, **42**:295–305.
65. Saha S, Yoshida S, Ohba K, Matsui K, Matsuda T, Takeshita F, Umeda K, Tamura Y, Okuda K, Klinman D, Xin KQ, Okuda K: **A fused gene of nucleoprotein (NP) and herpes simplex virus genes(VP22) induces highly protective immunity against different subtypes of influenza virus.** *Virology* 2006, **354**:48–57.
66. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, *et al*: **EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.** *Ann Rheum Dis* 2010, **69**:964–975.
67. Kirwan JR, Bijlsma JW, Boers M, Shea BJ: **Effect of glucocorticoids on radiological progression in rheumatoid arthritis.** *Cochrane Database Syst Rev* 2007:CD006356.
68. Salemi S, D'Amelio R: **Are anti-infectious vaccinations safe and effective in patients with autoimmunity?** *Int Rev Immunol* 2010, **29**:270–314.
69. Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M: **EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.** *Ann Rheum Dis* 2011, **70**:414–422.
70. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkman ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG: **2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis.** *Arthritis Care Res (Hoboken)* 2012, **64**:475–487.

doi:10.1186/1479-5876-12-77

Cite this article as: Germano *et al.*: Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF- α antagonists. *Journal of Translational Medicine* 2014 **12**:77.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

